Infinity Pharmaceuticals enters licence agreement with BioImage  

The US based pharmaceutical company has entered a licence agreement with Denmark's BioImage on using BioImage technology for drug development

US based Infinity Pharmaceuticals has entered a licence agreement with Danish biotech company BioImage on using BioImage's Redistribution technology for drug development. BioImage has developed and patented a unique technology which makes it possible to study the function of proteins in living cells.


BioImage is currently using its technology to test several thousand substances every day to identify possible drug candidates. BioImage is a spin-off from the Danish healthcare concern Novo Nordisk. The company is based in Copenhagen and employs 50 people. BioImage's investors include Apax Partners, Abingworth Management and Novo A/S. The news is reported by BiotechDenmark online.


Link > BioImage

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×